StockData
LeonaBio, Inc. logo

LeonaBio, Inc. (LONA) stock

LONANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$2.76−0.47 (-14.55%)

Close on Nov 17, 2026Market cap $26.00MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
$26.00M
P/E ratio
–
Price to sales
–
Price to book
0.77
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$141.46M
EPS, diluted
-$19.72
Book value per share
$1.42
Diluted shares
24M

Trading

Next earnings
Q3 FY2026, expected soon
Previous close
$3.23
Open
$3.17
Day's range
$2.75 – $3.32
Volume
24,683
Average volume (20 days)
60,194
52-week range
$2.21 – $14.21
RSI (14 days)
22.4
Volatility (1 year)
120.6%
Relative volume
0.16×

Market cap history

Month-end market cap since 2020, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodLONAS&P 500DifferenceLONA per yearS&P 500 per year
1 month-46.9%-4.0%−42.9 pts
3 months-64.2%-5.0%−59.2 pts
Year to date-63.5%+8.2%−71.8 pts
1 year-40.0%+11.2%−51.2 pts
3 years-83.7%+68.5%−152.1 pts-45.3%+19.0%
5 years-98.2%+67.3%−165.5 pts-55.1%+10.8%

Eight years at a glance

Fiscal years 2018 to 2025 and trailing twelve months, USD

Operating income

-$122.11M

Net income

-$141.46M

EPS, diluted

-$19.72

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases LeonaBio filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About LeonaBio

Biological Products, (No Diagnostic Substances)

Athira Pharma is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for diseases with substantial unmet medical needs, primarily targeting neurological disorders and treatment-resistant oncology. Its lead oncology candidate is lasofoxifene, an orally bioavailable selective estrogen receptor modulator in Phase 3 clinical evaluation for patients with ESR1-mutated metastatic breast cancer. In neurology, the company develops ATH-1105, an orally administered small-molecule positive modulator of the hepatocyte growth factor system being prepared for Phase 2 clinical trials in individuals with amyotrophic lateral sclerosis. The company additionally explores early-stage pipeline assets, such as ATH-1020, to improve neuronal function. Target patient populations consist of individuals living with neurodegenerative conditions and advanced breast cancer.

Company profile, executives and history

LeonaBio stock: common questions

What is LeonaBio's stock price?

LONA closed at $2.76 on Nov 17, 2026, down 14.55% on the day. Over the past 52 weeks it traded between $2.21 and $14.21.

What is LeonaBio's market cap?

LeonaBio was worth $26.00M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

What is LONA's P/E ratio?

LeonaBio lost money over the twelve months to Jun 30, 2026 (diluted EPS -$19.72), so it has no meaningful P/E ratio.

Does LeonaBio pay a dividend?

No. LeonaBio has not paid a cash dividend over the last twelve months.

When does LeonaBio report earnings next?

LeonaBio's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.

How has LONA stock performed over the past year?

Including dividends, LONA returned -40.0% over the past year, against +11.2% for the S&P 500.

Who are LeonaBio's competitors?

Companies most similar to LeonaBio by business, industry and size include NMRA, AVXL, EIKN, CCCC, CGTX.

See a number that looks wrong?